Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis

References

• Dunckley T, Huentelman MJ, Craig DW, Pearson JV, Szelinger S, Joshipura K, et al. Whole-genome analysis of sporadic amyotrophic lateral sclerosis. The New England Journal of Medicine. 2007; 357: 775–88
   PubMed Web of Science ®Google Scholar
• Valentine JS, Doucette PA, Potter SZ. Copper-zinc superoxide dismutase and amyotrophic lateral sclerosis. Annual Review of Biochemistry. 2005; 74: 563–93
   PubMed Web of Science ®Google Scholar
• Valentine JS, Hart PJ. Misfolded Cu/Zn SOD and amyotrophic lateral sclerosis. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100: 3617–22
   PubMed Web of Science ®Google Scholar
• Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu/Zn superoxide dismutase are associated with familial amyotrophic lateral sclerosis. Nature. 1993; 362: 59–62
   PubMed Web of Science ®Google Scholar
• Ratovitski T, Corson LB, Strain J, Wong P, Cleveland DW, Culotta VC, et al. Variation in the biochemical/biophysical properties of mutant superoxide dismutase 1 enzymes and the rate of disease progression in familial amyotrophic lateral sclerosis kindreds. Human Molecular Genetics. 1999; 8: 1451–60
   PubMed Web of Science ®Google Scholar
• Wang J, Slunt H, Gonzales V, Fromholt D, Coonfield M, Copeland NG, et al. Copper-binding-site-null SOD1 causes ALS in transgenic mice: aggregates of non-native SOD1 delineate a common feature. Human Molecular Genetics. 2003; 12: 2753–64
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, McKenna-Yasek D, Sapp PE, Chin W, Geller B, Hayden DL, et al. Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Annals of Neurology. 1997; 41: 210–21
   PubMed Web of Science ®Google Scholar
• Gurney ME, Pu H, Chiu AY, Canto MCD, Polchow CY, Alexander DD, et al. Motor neuron degeneration in mice that express a human Cu/Zn superoxide dismutase mutation. SCIENCE. 1994; 264: 1772–5
   PubMed Web of Science ®Google Scholar
• Dal Canto MC, Gurney ME. A low expressor line of transgenic mice carrying a mutant human Cu/Zn superoxide dismutase (SOD1) gene develops pathological changes that most closely resemble those in human amyotrophic lateral sclerosis. Acta Neuropathologica. 1997; 93: 537–50
   PubMed Web of Science ®Google Scholar
• Reaume AG, Elliott JL, Hoffman EK, Kowall NW, Ferrante RJ, Siwek DF, et al. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nature Genetics. 1996; 13: 43–7
   PubMed Web of Science ®Google Scholar
• Spreux-Varoquaux O, Bensimon G, Lacomblez L, Salachas F, Pradat PF, Le Forestier N, et al. Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients. J Neurol Sci JID-0375403. 2002; 193: 73–8
   PubMed Web of Science ®Google Scholar
• Carriedo SG, Yin HZ, Weiss JH. Motor neurons are selectively vulnerable to AMPA/kainate receptor-mediated injury in vitro. J Neurosci JID-8102140. 1996; 16: 4069–79
   PubMed Web of Science ®Google Scholar
• Schubert D, Piasecki D. Oxidative glutamate toxicity can be a component of the excitotoxicity cascade. Journal of Neuroscience. 2001; 21: 7455–62
   PubMed Web of Science ®Google Scholar
• Tarabal O, Caldero J, Llado J, Oppenheim RW, Esquerda JE. Long-lasting aberrant tubulovesicular membrane inclusions accumulate in developing motor neurons after a sublethal excitotoxic insult: a possible model for neuronal pathology in neurodegenerative disease. Journal of Neuroscience. 2001; 21: 8072–81
   PubMed Web of Science ®Google Scholar
• Bilak MM, Kuncl RW. Delayed application of IGF-I and GDNF can rescue already injured postnatal motor neurons. Neuroreport. 2001; 12: 2531–5
   PubMed Web of Science ®Google Scholar
• Vincent AM, Mobley BC, Hiller A, Feldman EL. IGF-I prevents glutamate-induced motor neuron programmed cell death. Neurobiology of Disease. 2004; 16: 407–16
   PubMed Web of Science ®Google Scholar
• Bensimon G, Lacomblez L, Meininger V, Group ALRS. A controlled trial of riluzole in amyotrophic lateral sclerosis. New England Journal of Medicine. 1994; 330: 585–91
   PubMed Web of Science ®Google Scholar
• Feldman EL, Sullivan KA, Kim B, Russell JW. Insulin-like growth factors regulate neuronal differentiation and survival. Neurobiology of Disease. 1997; 4: 201–14
   PubMed Web of Science ®Google Scholar
• Vincent AM, Feldman EL, Song DK, Jung V, Schild A, Zhang W, et al. Adeno-associated viral-mediated insulin-like growth factor delivery protects motor neurons in vitro. Neuro Molecular Medicine. 2004; 6: 79–85
   PubMed Web of Science ®Google Scholar
• Dore S, Kar S, Quirion R. Rediscovering an old friend, IGF-I: potential use in the treatment of neurodegenerative diseases. Trends in Neurosciences. 1997; 20: 326–31
   PubMed Web of Science ®Google Scholar
• Duan C. Specifying the cellular responses to IGF signals: roles of IGF-binding proteins. The Journal of Endocrinology. 2002; 175: 41–54
   PubMed Web of Science ®Google Scholar
• LeRoith D, Werner H, Beitner-Johnson D, Roberts CT, Jr. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocrine Reviews. 1995; 16: 143–63
   PubMed Web of Science ®Google Scholar
• De Meyts P, Wallach B, Christoffersen CT, Urso B, Gronskov K, Latus LJ, et al. The insulin-like growth factor-I receptor. Structure, ligand-binding mechanism and signal transduction. Hormone Research. 1994; 42: 152–69
   PubMed Web of Science ®Google Scholar
• Parrizas M, Saltiel AR, LeRoith D. Insulin-like growth factor-I inhibits apoptosis using the phosphatidylinositol 3'-kinase and mitogen-activated protein kinase pathways. The Journal of Biological Chemistry. 1997; 272: 154–61
   PubMed Web of Science ®Google Scholar
• Derijard B, Hibi M, Wu IH, Barrett T, Su B, Deng T, et al. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell. 1994; 76: 1025–37
   PubMed Web of Science ®Google Scholar
• Floyd S, Favre C, Lasorsa FM, Leahy M, Trigiante G, Stroebel P, et al. The insulin-like growth factor-I-mTOR signaling pathway induces the mitochondrial pyrimidine nucleotide carrier to promote cell growth. Molecular Biology of the Cell. 2007; 18: 3545–55
   PubMed Web of Science ®Google Scholar
• Han J, Lee JD, Bibbs L, Ulevitch RJ. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science (New York. NY) 1994; 265: 808–11
   PubMed Web of Science ®Google Scholar
• Rouse J, Cohen P, Trigon S, Morange M, Alonso-Llamazares A, Zamanillo D, et al. A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins. Cell. 1994; 78: 1027–37
   PubMed Web of Science ®Google Scholar
• Siddle K, Urso B, Niesler CA, Cope DL, Molina L, Surinya KH, et al. Specificity in ligand binding and intracellular signaling by insulin and insulin-like growth factor receptors. Biochemical Society Transactions. 2001; 29: 513–25
   PubMed Web of Science ®Google Scholar
• Kurmasheva RT, Houghton PJ. IGF-I mediated survival pathways in normal and malignant cells. Biochimica et Biophysica Acta. 2006; 1766: 1–22
   PubMed Web of Science ®Google Scholar
• Laviola L, Natalicchio A, Giorgino F. The IGF-I signaling pathway. Curr Pharm Des. 2007; 13: 663–9
   PubMed Web of Science ®Google Scholar
• Feldman EL, Sullivan KA, Kim B, Russell JW. Insulin-like growth factors regulate neuronal differentiation and survival. Neurobiology of Disease. 1997; 4: 201–14
   PubMed Web of Science ®Google Scholar
• Leinninger GM, Backus C, Uhler MD, Lentz SI, Feldman EL. Phosphatidylinositol 3-kinase and Akt effectors mediate insulin-like growth factor-I neuroprotection in dorsal root ganglia neurons. FASEB J. 2004; 18: 1544–6
   PubMed Web of Science ®Google Scholar
• Leinninger GM, Russell JW, van Golen CM, Berent A, Feldman EL. Insulin-like growth factor-I (IGF-I) regulates glucose-induced mitochondrial depolarization and apoptosis in human neuroblastoma. Cell Death and Differentiation. 2004; 11: 885–96
   PubMed Web of Science ®Google Scholar
• Vincent AM, Feldman EL. Control of cell survival by IGF signaling pathways. Growth Hormone and IGF Research. 2002; 12: 193–7
   PubMed Web of Science ®Google Scholar
• Ozdinler PH, Macklis JD. IGF-I specifically enhances axon outgrowth of corticospinal motor neurons. Nature Neuroscience. 2006; 9: 1371–81
   PubMed Web of Science ®Google Scholar
• Vincent AM, Feldman EL, Song DK, Jung V, Schild A, Zhang W, et al. Adeno-associated viral-mediated insulin-like growth factor delivery protects motor neurons in vitro. Neuromolecular Medicine. 2004; 6: 79–86
   PubMed Web of Science ®Google Scholar
• Bilak MM, Corse AM, Kuncl RW. Additivity and potentiation of IGF-I and GDNF in the complete rescue of postnatal motor neurons. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001; 2: 83–91
   PubMed Web of Science ®Google Scholar
• Corse AM, Bilak MM, Bilak SR, Lehar M, Rothstein JD, Kuncl RW. Preclinical testing of neuroprotective neurotrophic factors in a model of chronic motor neuron degeneration. Neurobiology of Disease. 1999; 6: 335–46
   PubMed Web of Science ®Google Scholar
• Zhao W, Xie W, Xiao Q, Beers DR, Appel SH. Protective effects of an anti-inflammatory cytokine, interleukin-4, on motor neuron toxicity induced by activated microglia. Journal of Neurochemistry. 2006; 99: 1176–87
   PubMed Web of Science ®Google Scholar
• Xiao Q, Zhao W, Beers DR, Yen AA, Xie W, Henkel JS, et al. Mutant SOD1-G93A microglia are more neurotoxic relative to wild-type microglia. Journal of Neurochemistry. 2007; 102: 2008–19
   PubMed Web of Science ®Google Scholar
• Hantai D, Akaaboune M, Lagord C, Murawsky M, Houenou LJ, Festoff BW, et al. Beneficial effects of insulin-like growth factor-I on wobbler mouse motor neuron disease. Journal of the Neurological Sciences. 1995; 129: 122–6
   PubMed Web of Science ®Google Scholar
• Iwasaki Y, Ikeda K. Prevention by insulin-like growth factor-I and riluzole in motor neuron death after neonatal axotomy. Journal of the Neurological Sciences. 1999; 169: 148–55
   PubMed Web of Science ®Google Scholar
• Torres-Aleman I, Barrios V, Berciano J. The peripheral insulin-like growth factor system in amyotrophic lateral sclerosis and in multiple sclerosis. Neurology. 1998; 50: 772–6
   PubMed Web of Science ®Google Scholar
• Kerkhoff H, Hassan SM, Troost D, van Etten RW, Veldman H, Jennekens FGI. Insulin-like and fibroblast growth factors in spinal cords, nerve roots and skeletal muscle of human controls and patients with amyotrophic lateral sclerosis. Acta Neuropathologica. 1994; 87: 411–21
   PubMed Web of Science ®Google Scholar
• Chung YH, Joo KM, Shin CM, Lee YJ, Shin DH, Lee KH, et al. Immunohistochemical study on the distribution of insulin-like growth factor-I (IGF-I) receptor in the central nervous system of SOD1(G93A) mutant transgenic mice. Brain Research. 2003; 994: 253–9
   PubMed Web of Science ®Google Scholar
• Arnold PM, Ma JY, Citron BA, Zoubine MN, Festoff BW. Selective developmental regulation of gene expression for insulin-like growth factor binding proteins in mouse spinal cord. Spine. 2000; 25: 1765–70
   PubMed Web of Science ®Google Scholar
• Wilczak N, de Vos RA, de Keyser J. Free insulin-like growth factor (IGF)-I and IGF binding proteins 2, 5, and 6 in spinal motor neurons in amyotrophic lateral sclerosis. Lancet. 2003; 361: 1007–11
   PubMed Web of Science ®Google Scholar
• Messi ML, Clark HM, Prevette DM, Oppenheim RW, Delbono O. The lack of effect of specific overexpression of IGF-I in the central nervous system or skeletal muscle on pathophysiology in the G93A SOD-1 mouse model of ALS. Exp Neurol. 2007; 207: 52–63
   PubMed Web of Science ®Google Scholar
• Corti S, Locatelli F, Papadimitriou D, Del Bo R, Nizzardo M, Nardini M, et al. Neural stem cells LewisX+ CXCR4+ modify disease progression in an amyotrophic lateral sclerosis model. Brain. 2007; 130: 1289–305
   PubMed Web of Science ®Google Scholar
• Yan J, Xu L, Welsh AM, Chen D, Hazel T, Johe K, et al. Combined immunosuppressive agents or CD4 antibodies prolong survival of human neural stem cell grafts and improve disease outcomes in amyotrophic lateral sclerosis transgenic mice. Stem Cells (Dayton, Ohio) 2006; 24: 1976–85
   PubMed Web of Science ®Google Scholar
• Hantai D, Akaaboune M, Lagord C, Murawsky M, Houenou LJ, Festoff BW, et al. Beneficial effects of insulin-like growth factor-I on wobbler mouse motor neuron disease. J Neurol Sci. 1995; 129: 122–6
   PubMed Web of Science ®Google Scholar
• Nagano I, Ilieva H, Shiote M, Murakami T, Yokoyama M, Shoji M, et al. Therapeutic benefit of intrathecal injection of insulin-like growth factor-I in a mouse model of amyotrophic lateral sclerosis. Journal of the Neurological Sciences. 2005; 235: 61–8
   PubMed Web of Science ®Google Scholar
• Narai H, Nagano I, Ilieva H, Shiote M, Nagata T, Hayashi T, et al. Prevention of spinal motor neuron death by insulin-like growth factor-I associating with the signal transduction systems in SODG-93A transgenic mice. Journal of Neuroscience Research. 2005; 82: 452–7
   PubMed Web of Science ®Google Scholar
• Boulis NM, Willmarth NE, Song DK, Feldman EL, Imperiale MJ. Intraneural colchicine inhibition of adenoviral and adeno-associated viral vector remote spinal cord gene delivery. Neurosurgery. 2003; 52: 381–7
   PubMed Web of Science ®Google Scholar
• Kaspar BK, Erickson D, Schaffer D, Hinh L, Gage FH, Peterson DA. Targeted retrograde gene delivery for neuronal protection. Mol Ther. 2002; 5: 50–6
   PubMed Web of Science ®Google Scholar
• Boillee S, Cleveland DW. Gene therapy for ALS delivers. Trends in Neurosciences. 2004; 27: 235–8
   PubMed Web of Science ®Google Scholar
• Kaspar BK, Llado J, Sherkat N, Rothstein JD, Gage FH. Retrograde viral delivery of IGF-I prolongs survival in a mouse ALS model. Science (New York, NY) 2003; 301: 839–42
   Google Scholar
• Dobrowolny G, Giacinti C, Pelosi L, Nicoletti C, Winn N, Barberi L, et al. Muscle expression of a local IGF-I isoform protects motor neurons in an ALS mouse model. J Cell Biol. 2005; 168: 193–9
   PubMed Web of Science ®Google Scholar
• Gorecki DC, Beresewicz M, Zablocka B. Neuroprotective effects of short peptides derived from the insulin-like growth factor-I. Neurochemistry International. 2007; 51: 451–8
   PubMed Web of Science ®Google Scholar
• Aperghis M, Johnson IP, Cannon J, Yang SY, Goldspink G. Different levels of neuroprotection by two insulin-like growth factor-I splice variants. Brain Res. 2004; 29: 213–8
   Google Scholar
• Ates K, Yang SY, Orrell RW, Sinanan AC, Simons P, Solomon A, et al. The IGF-I splice variant MGF increases progenitor cells in ALS, dystrophic, and normal muscle. FEBS Letters. 2007; 581: 2727–32
   PubMed Web of Science ®Google Scholar
• Adamo ML, Neuenschwander S, LeRoith D, Roberts CT, Jr. Structure, expression, and regulation of the IGF-I gene. Advances in Experimental Medicine and Biology. 1993; 343: 1–11
   PubMedGoogle Scholar
• Musaro A, McCullagh K, Paul A, Houghton L, Dobrowolny G, Molinaro M, et al. Localized IGF-I transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nature Genetics. 2001; 27: 195–200
   PubMed Web of Science ®Google Scholar
• Braunstein GD, Reviczky AL. Serum insulin-like growth factor-I levels in amyotrophic lateral sclerosis. Journal of Neurology. Neurosurgery and Psychiatry. 1987; 50: 792–4
   PubMed Web of Science ®Google Scholar
• Bilic E, Bilic E, Rudan I, Kusec V, Zurak N, Delimar D, et al. Comparison of the growth hormone, IGF-I, and insulin in cerebrospinal fluid and serum between patients with motor neuron disease and healthy controls. Eur J Neurol. 2006; 13: 1340–5
   PubMed Web of Science ®Google Scholar
• Morselli LL, Bongioanni P, Genovesi M, Licitra R, Rossi B, Murri L, et al. Growth hormone secretion is impaired in amyotrophic lateral sclerosis. Clinical Endocrinology. 2006; 65: 385–8
   PubMed Web of Science ®Google Scholar
• Ono S, Hu J, Imai T, Shimizu N, Tsumura M, Nakagawa H. Increased expression of insulin-like growth factor-I in skin in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2000; 69: 199–203
   PubMed Web of Science ®Google Scholar
• Hosback S, Hardiman O, Nolan CM, Doyle MA, Gorman G, Lynch C, et al. Circulating insulin-like growth factors and related binding proteins are selectively altered in amyotrophic lateral sclerosis and multiple sclerosis. Growth Horm IGF Res. 2007; 17: 472–9
   PubMed Web of Science ®Google Scholar
• Adem A, Ekblom J, Gillberg PG. Growth factor receptors in amyotrophic lateral sclerosis. Molecular Neurobiology. 1994; 9: 225–31
   PubMed Web of Science ®Google Scholar
• Adem A, Ekblom J, Gillberg PG, Jossan SS, Höög A, Winblad B, et al. Insulin-like growth factor-I receptors in human spinal cord: changes in amyotrophic lateral sclerosis. J Neural Transm. 1994; 97: 73–84
   PubMed Web of Science ®Google Scholar
• Dore S, Krieger C, Kar S, Quirion R. Distribution and levels of insulin-like growth factor (IGF-I and IGF-II) and insulin receptor binding sites in the spinal cords of amyotrophic lateral sclerosis (ALS) patients. Brain Res Mol Brain Res. 1996; 41: 128–33
   PubMedGoogle Scholar
• Kihira T, Suzuki A, Kubo T, Miwa H, Kondo T. Expression of insulin-like growth factor-II and leukemia inhibitory factor antibody immunostaining on the ionized calcium-binding adaptor molecule 1-positive microglias in the spinal cord of amyotrophic lateral sclerosis patients. Neuropathology. 2007; 27: 257–68
   PubMed Web of Science ®Google Scholar
• Traynor BJ, Bruijn L, Conwit R, Beal F, O'Neill G, Fagan SC, et al. Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology. 2006; 67: 20–7
   PubMed Web of Science ®Google Scholar
• Borasio GD, Robberecht W, Leigh PN, Emile J, Guiloff RJ, Jerusalem F, et al. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology. 1998; 51: 583–6
   PubMed Web of Science ®Google Scholar
• Lai EC, Felice KJ, Festoff BW, Gawel MJ, Gelinas DF, Kratz R, et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology. 1997; 49: 1621–30
   PubMed Web of Science ®Google Scholar
• Mitchell JD, Wokke JH, Borasio GD. Recombinant human insulin-like growth factor-I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2002: CD002064.
   Google Scholar
• Nagano I, Shiote M, Murakami T, Kamada H, Hamakawa Y, Matsubara E, et al. Beneficial effects of intrathecal IGF-I administration in patients with amyotrophic lateral sclerosis. Neurological Research. 2005; 27: 768–72
   PubMed Web of Science ®Google Scholar
• Tanaka M, Sawada M, Miura M, Marunouchi T. Insulin-like growth factor-I analogue prevents apoptosis mediated through an interleukin-1 beta converting enzyme (caspase-1)-like protease of cerebellar external granular layer neurons: developmental stage-specific mechanisms of neuronal cell death. Neuroscience. 1998; 84: 89–100
   PubMed Web of Science ®Google Scholar
• Ekestern E. Neurotrophic factors and amyotrophic lateral sclerosis. Neurodegenerative Diseases. 2004; 1: 88–100
   PubMed Web of Science ®Google Scholar
• Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science (New York, NY) 1993; 262: 689–95
   Google Scholar
• Rothstein JD, Tsai G, Kuncl RW. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Annals of Neurology. 1990; 28: 18–25
   PubMed Web of Science ®Google Scholar
• Appel SH, Smith RG, Engelhardt JI, Stefani E. Evidence for autoimmunity in amyotrophic lateral sclerosis. Journal of the Neurological Sciences. 1994; 124(Suppl)14–9
   PubMed Web of Science ®Google Scholar
• Appel SH, Engelhardt JI, Garcia J, Stefani E. Autoimmunity and ALS: a comparison of animal models of immune-mediated motor neuron destruction and human ALS. Advances in Neurology. 1991; 56: 405–12
   PubMedGoogle Scholar
• Lin H, Zhai J, Canete-Soler R, Schlaepfer WW. 3′ untranslated region in a light neurofilament (NF-L) mRNA triggers aggregation of NF-L and mutant superoxide dismutase-1 proteins in neuronal cells. J Neurosci. 2004; 24: 2716–26
   PubMed Web of Science ®Google Scholar
• Ge WW, Wen W, Strong W, Leystra-Lantz C, Strong MJ. Mutant copper-zinc superoxide dismutase binds to and destabilizes human low molecular weight neurofilament mRNA. The Journal of Biological Chemistry. 2005; 280: 118–24
   PubMed Web of Science ®Google Scholar
• Dupuis L, Gonzalez de Aguilar JL, Oudart H, de Tapia M, Barbeito L, Loeffler JP. Mitochondria in amyotrophic lateral sclerosis: a trigger and a target. Neurodegenerative Diseases. 2004; 1: 245–54
   PubMed Web of Science ®Google Scholar
• Bacman SR, Bradley WG, Moraes CT. Mitochondrial involvement in amyotrophic lateral sclerosis: trigger or target?. Molecular Neurobiology. 2006; 33: 113–31
   PubMed Web of Science ®Google Scholar
• Yim MB, Kang JH, Yim HS, Kwak HS, Chock PB, Stadtman ER. A gain-of-function of an amyotrophic lateral sclerosis-associated Cu/Zn-superoxide dismutase mutant: an enhancement of free radical formation due to a decrease in Km for hydrogen peroxide. Proceedings of the National Academy of Sciences of the United States of America. 1996; 93: 5709–14
   PubMed Web of Science ®Google Scholar
• Liu D, Bao F, Wen J, Liu J. Mutation of superoxide dismutase elevates reactive species: comparison of nitration and oxidation of proteins in different brain regions of transgenic mice with amyotrophic lateral sclerosis. Neuroscience. 2007; 146: 255–64
   PubMed Web of Science ®Google Scholar
• Gonzalez de Aguilar JL, Echaniz-Laguna A, Fergani A, Rene F, Meininger V, Loeffler JP, et al. Amyotrophic lateral sclerosis: all roads lead to Rome. Journal of Neurochemistry. 2007; 101: 1153–60
   PubMed Web of Science ®Google Scholar
• Pasinelli P, Brown RH. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nature Reviews. 2006; 7: 710–23
   Web of Science ®Google Scholar
• Valdmanis PN, Rouleau GA. Genetics of familial amyotrophic lateral sclerosis. Neurology. 2008; 70: 144–52
   PubMed Web of Science ®Google Scholar
• Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993; 362: 59–62
   PubMed Web of Science ®Google Scholar
• Hadano S, Hand CK, Osuga H, Yanagisawa Y, Otomo A, Devon RS, et al. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis. Nature Genetics. 2001; 29: 166–73
   PubMed Web of Science ®Google Scholar
• Yang Y, Hentati A, Deng HX, Dabbagh O, Sasaki T, Hirano M, et al. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nature Genetics. 2001; 29: 160–5
   PubMed Web of Science ®Google Scholar
• Munch C, Sedlmeier R, Meyer T, Homberg V, Sperfeld AD, Kurt A, et al. Point mutations of the p150 subunit of dynactin (DCTN1) gene in ALS. Neurology. 2004; 63: 724–6
   PubMed Web of Science ®Google Scholar
• Puls I, Jonnakuty C, LaMonte BH, Holzbaur EL, Tokito M, Mann E, et al. Mutant dynactin in motor neuron disease. Nature Genetics. 2003; 33: 455–6
   PubMed Web of Science ®Google Scholar
• Greenway MJ, Andersen PM, Russ C, Ennis S, Cashman S, Donaghy C, et al. ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis. Nature Genetics. 2006; 38: 411–3
   PubMed Web of Science ®Google Scholar
• Chen YZ, Bennett CL, Huynh HM, Blair IP, Puls I, Irobi J, et al. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). American Journal of Human Genetics. 2004; 74: 1128–35
   PubMed Web of Science ®Google Scholar
• Nishimura AL, Mitne-Neto M, Silva HC, Richieri-Costa A, Middleton S, Cascio D, et al. A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. American Journal of Human Genetics. 2004; 75: 822–31
   PubMed Web of Science ®Google Scholar